- Home
- AJG vs MRNA Comparison
AJG vs MRNA Comparison
Compare AJG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AJG | MRNA |
|---|---|---|
| Founded | 1927 | 2010 |
| Country | United States | United States |
| Employees | 706000 | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0B | 61.6B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AJG | MRNA |
|---|---|---|
| Price | $253.13 | $214.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 23 |
| Target Price | ★ $283.33 | $123.61 |
| AVG Volume (30 Days) | 1.2M | ★ 14.8M |
| Earning Date | 10-29-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 4.41 | N/A |
| Revenue | $6,159,600,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $27.69 | $8.09 |
| Revenue Next Year | $8.70 | $16.06 |
| P/E Ratio | $56.63 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $190.75 | $22.28 |
| 52 Week High | $284.33 | $242.29 |
Technical Indicators
Market Signals| Indicator | AJG | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.42 | 60.63 |
| Support Level | $239.44 | $45.39 |
| Resistance Level | $259.26 | N/A |
| Average True Range (ATR) | 5.38 | 16.26 |
| MACD | 3.25 | 0.12 |
| Stochastic Oscillator | 92.56 | 51.15 |
Price Performance
Historical ComparisonAbout AJG Arthur J. Gallagher & Co.
Founded in 1927 as a one-person agency, Gallagher's primary business is insurance brokerage, with a focus on serving middle-market companies. The company's risk management segment provides third-party claims adjustment to companies that choose to self-insure. Gallagher has about 72,000 employees and generates about a third of its revenue internationally, primarily in Australia, Canada, New Zealand, and the UK.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.